FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

| Washington, [| D.C. 20549 |
|---------------|------------|
|---------------|------------|

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

| Instruction 1(b) | | | Filed pursuant to Section 16(a) of the Securities Exchange Act of 193 or Section 30(h) of the Investment Company Act of 1940 | 4 | nours p | er resp | onse: 0.5 | | | |
|---------------------------------|-----------|-----------------------|--|--|---|---------|---------------------------|--|--|--|
| 1. Name and Addr Lowenthal I | • | g Person [*] | 2. Issuer Name and Ticker or Trading Symbol ARS Pharmaceuticals, Inc. [SPRY] | | ationship of Reporting k all applicable) Director | Perso | on(s) to Issuer | | | |
| (Last) C/O ARS PHA | (First) | (Middle) | 3. Date of Earliest Transaction (Month/Day/Year) 03/22/2024 | X | Officer (give title below) PRESIDENT | ANI | Other (specify below) CEO | | | |
| 11682 EL CAN | MINO REAL | , SUITE 120 | 4. If Amendment, Date of Original Filed (Month/Day/Year) | 4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Line) | | | | | | |
| (Street) | | | | X | Form filed by One | Repor | ting Person | | | |
| SAN DIEGO | CA | 92130 | | | Form filed by More Person | than | One Reporting | | | |
| (City) | (State) | (Zip) | Rule 10b5-1(c) Transaction Indication | 7 | | | | | | |
| | | | | | | | | | | |

| (City) | State) | (Zip) | Rule 10b5-1(c) Transaction Indication | | | | | | | | |
|------------------------------|----------|--|---|---|--------|------------------------------|-----------------------|---------------------------------------|--|--|--|
| | | | Check this box satisfy the affirm | o indicat native de | e that | a transaction was | as made ule 10b5- | pursuant to a co 1(c). See Instruc | ontract, instruction or ction 10. | written plan that i | s intended to |
| | Ta | ble I - Non-Derivat | ive Securities | Acqui | red, | Disposed | of, or | Beneficial | lly Owned | | |
| 1. Title of Security (Instr. | nstr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | | 4. Securities Disposed Of | Acquired (D) (Inst | d (A) or r. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
| | | | | Code | v | Amount | (A) or (D) | Price | Reported Transaction(s) (Instr. 3 and 4) | | |
| Common Stock | | | | | | | | | 4,126,822 | D | |
| Common Stock | | 03/22/2024 | | S | | 1,017(1) | D | \$9.0298(2) | 1,745,082 | I | By Sarina Tanimoto Charitable Remainder UniTrust Dated January 7, 2020 ⁽³⁾ |
| Common Stock | | 03/22/2024 | | S | | 1,326(1) | D | \$9.0132(4) | 1,996,131 | I | By Lowenthal- Tanimoto Family Trust U/A DTD 4/3/2006 ⁽⁵⁾ |
| Common Stock | | 03/25/2024 | | S | | 47,635 ⁽¹⁾ | D | \$9.1238(6) | 1,697,447 | I | By Sarina Tanimoto Charitable Remainder UniTrust Dated January 7, 2020 ⁽³⁾ |
| Common Stock | | 03/25/2024 | | S | | 47,632 ⁽¹⁾ | D | \$9.1236 ⁽⁷⁾ | 1,948,499 | I | By Lowenthal- Tanimoto Family Trust U/A DTD 4/3/2006 ⁽⁵⁾ |
| Common Stock | | | | | | | | | 1,696,494 | I | By Richard E. Lowenthal Charitable Remainder UniTrust Dated January 7, 2020 ⁽⁸⁾ |
| Common Stock | | | | | | | | | 3,276,854 | I | By Spouse |

| | Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | | | | | | | | | | | | | | |
|---|--|--|---|------------------------------|---|----------------|-----|--|--------------------|---|--|---|--|--|--|
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transa Code (8) | | 5. Number 6. I | | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
| | | | | Code | v | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | | | |

Explanation of Responses:

- 1. The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023.
- 2. The weighted average sale price for the transaction reported was \$9.0298, and the range of prices were between \$9.00 and \$9.06. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- 3. The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
- 4. The weighted average sale price for the transaction reported was \$9.0132, and the range of prices were between \$9.00 and \$9.07. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- 5. The shares are held in trust for the benefit of the Reporting Person and his spouse. The Reporting Person and his spouse are trustees of the trust.
- 6. The weighted average sale price for the transaction reported was \$9.1238, and the range of prices were between \$9.03 and \$9.36. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- 7. The weighted average sale price for the transaction reported was \$9.1236, and the range of prices were between \$9.03 and \$9.36. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- 8. The Reporting Person is trustee of the trust.

/s/ Kathleen Scott, Attorneyin-Fact 03/26/2024

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.